Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals [Yahoo! Finance]
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $2.00 price target on the stock, down previously from $27.00.
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.